niPSC HDF16, niPSC-16.2b
CSCIi001-A
General
Cell Line |
|
| hPSCreg name | CSCIi001-A |
| Cite as: | CSCIi001-A (RRID:CVCL_C2VK) |
| Alternative name(s) |
niPSC HDF16, niPSC-16.2b
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 11th April 2024 |
| Notes | A population of naive iPSCs generated by RNA reprogramming from human fibroblasts [ThermoFisher Scientific product number C0135C, Adult Human Dermal Fibroblasts (HDFa), lot number 1640478 (31 yo F)] as described by Bredenkamp et al. doi. 10.1016/j.stemcr.2019.10.009 |
| User feedback | |
Provider |
|
| Generator | Wellcome Trust - MRC Stem Cell Institute (CSCI) |
| Owner | University of Cambridge (CAM) |
| Distributors | |
| Derivation country | United Kingdom |
External Databases |
|
| BioSamples | SAMEA115462286 |
| Cellosaurus | CVCL_C2VK |
| Wikidata | Q114312550 |
General Information |
|
| Publications | |
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 30-34 |
| Ethnicity | Not available |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Family history | No |
| Is the medical history available upon request? | No |
| Is clinical information available? | No |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA115462285 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Please provide contact information of the holder of the original Donor Information Sheet. | Thermo Fisher Scientific |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | https://www.thermofisher.com/order/catalog/product/C0135C |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Thermo Fisher |
| Approval number | The cells in this lot were derived from tissue obtained from accredited institutions. Consent was obtained by these institutions from the donor or the donor's legal next of kin, for use of the tissue and its derivatives for research purposes. |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | ReproCell |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell line name | Human dermal fibroblasts |
| Source cell type | |
| Source cell origin |
An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.
Synonyms
|
| Source cell line lot number |
1640478
|
| Age of donor (at collection) | 30-34 |
| Collected in | 2015 |
| Source cell line vendor | Thermo Fisher |
| Passage number reprogrammed | 5 |
Reprogramming method |
|
| Vector type | None |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
mRNA
|
Other |
|
| Selection criteria for clones | Bulk passaging |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex | |||||||||||||||||||||
| Feeder cells |
Mouse embryo fibroblasts |
|||||||||||||||||||||
| Passage method |
Enzymatically
Accutase
|
|||||||||||||||||||||
| O2 Concentration | 5 % | |||||||||||||||||||||
| CO2 Concentration | 7 % | |||||||||||||||||||||
| Medium |
Other medium:
Base medium: DMEM/F12/Neurobasal
Main protein source: Albumine Serum concentration: 0 % Supplements
|
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| NANOG |
Yes |
|
|
|
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
See Bredenkamp et al. doi. 10.1016/j.stemcr.2019.10.009
Transcriptome Characterisation
Differentiation Potency
In vitro directed differentiation
Protocol or reference
Bredenkamp reprogramming SCR 2019.pdf
Publication
In vitro directed differentiation
| Marker | Expressed |
| TBX6 |
Yes |
Protocol or reference
Bredenkamp reprogramming SCR 2019.pdf
Publication
In vitro directed differentiation
Protocol or reference
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XX
Passage number: >10
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.